Merck tops third-quarter estimates as Keytruda, Gardasil outperform

3

By Michael Erman NEW YORK, Oct 29 (Reuters) – Merck posted higher-than-expected third-quarter earnings on Thursday, driven by strong demand for its blockbuster cancer drug Keytruda and its HPV vaccine

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)